NEW YORK – Tecan Group announced Thursday that it will acquire certain assets related to ELISA immunoassays from Revvity subsidiary Cisbio Bioassays.
The purchase includes the manufacturing process of four ELISA kits, two of which are in vitro diagnostic products for specialty diagnostics and disease monitoring. The other two kits, CGA-EL-US-NG RUO and P3NP-EL-US RUO, are for research use only.
According to a statement from Tecan, the IVD products included in the purchase are the CGA-ELISA-NG assay that determines the presence and progression of neuroendocrine tumors in adults and the P3NP-ELISA test that measures the levels of N-terminal procollagen III peptide in serum, EDTA, or heparin plasma to assess collagen III synthesis and monitor the risk of liver fibrosis in psoriasis patients receiving methotrexate.
Tecan subsidiary IBL International signed a master distributorship agreement with Cisbio to resell the kits until the asset transfer is completed. Once the transfer is completed, IBL will have full responsibility for the manufacturing, distribution, and regulatory compliance of the kits, Tecan noted.
Financial and other terms of the deal were not disclosed.
"This strategic purchase aligns with our commitment to supporting customers with high-quality solutions while strengthening our portfolio in specialty diagnostics," Mukta Acharya, head of Tecan's Life Sciences business, said in a statement. "As regulatory requirements continue to evolve, we are proactively expanding our offering to ensure laboratories have access to reliable, compliant solutions that meet their needs today and in the future."